Candelo Estephania, Bohorquez-Caballero Anyull D, Avila-Castano Karol, Wadei Hani, Donaldson Angela M
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Jacksonville, Florida, USA.
Department of Transplant, Mayo Clinic, Jacksonville, Florida, USA.
Int Forum Allergy Rhinol. 2024 Dec;14(12):1953-1956. doi: 10.1002/alr.23429. Epub 2024 Aug 24.
The study found a higher incidence of chronic rhinosinusitis (CRS) and recalcitrant CRS in cadaveric organ transplant recipients compared to those receiving living donor transplants. Recipients of cadaveric transplants were 1.32 times more likely to develop CRS and 1.68 times more likely to develop medically recalcitrant CRS. Living kidney transplants significantly reduced the risk of developing CRS (OR = 0.12) and recalcitrant CRS (OR = 0.11), highlighting a potentially protective effect against these conditions. In contrast, cadaveric liver transplants were associated with an increased risk of CRS and medically recalcitrant CRS. Kaplan-Meier survival analysis indicated a significant difference in time to CRS onset between cadaveric and living donor transplants. Median time to CRS onset was longer for living donor recipients (21.1 months) compared to cadaveric recipients (15.6 months). This study underscores the need for transplant teams and otolaryngologist to consider donor type during transplant follow-up due to differing risks of CRS development.
该研究发现，与接受活体供体移植的患者相比，尸体器官移植受者中慢性鼻-鼻窦炎（CRS）和难治性CRS的发病率更高。尸体移植受者发生CRS的可能性是前者的1.32倍，发生药物难治性CRS的可能性是前者的1.68倍。活体肾移植显著降低了发生CRS（比值比=0.12）和难治性CRS（比值比=0.11）的风险，突出了对这些病症的潜在保护作用。相比之下，尸体肝移植与CRS和药物难治性CRS风险增加相关。Kaplan-Meier生存分析表明，尸体移植和活体供体移植在CRS发病时间上存在显著差异。活体供体受者CRS发病的中位时间（21.1个月）比尸体受者（15.6个月）更长。这项研究强调，由于CRS发生风险不同，移植团队和耳鼻喉科医生在移植随访期间需要考虑供体类型。
